BMY vs SNY

Bristol-Myers Squibb's Advanced Deterministic Scorecard shows a Piotroski F-Score of 4/9, indicating stable but not strong financial health, while the absence of an Altman Z-Score prevents a definitive distress risk assessment. The stock trades below its growth-based intrinsic value of $87.32 at $54.65, suggesting potential undervaluation, yet the high debt/equity ratio and inconsistent earnings performance temper optimism. Strong profitability metrics like 31.57% operating margin and 33.78% ROE are offset by weak recent earnings growth and bearish insider activity. Analysts consensus is a hold with a $56.96 target, implying limited upside, while the 4.59% dividend yield offers income appeal despite an elevated 83.5% payout ratio.

Sanofi presents a mixed profile characterized by a stable Piotroski F-Score of 4/9 and a very conservative debt-to-equity ratio of 0.28. While the stock trades near its Graham Number ($43.22), it is significantly above its growth-based intrinsic value ($16.66), suggesting a valuation premium. The most critical concern is the unsustainable dividend payout ratio of 96.04%, which threatens the long-term viability of the 5.04% yield. Despite a bearish technical trend (0/100), the low forward P/E of 9.09 and positive analyst targets provide a counter-balance to the current stagnation.